Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Voxel S.A. (VOX.WA)
PLN110.80
-0.20 (-0.18%)
PL WSE Healthcare Medical - Diagnostics & Research
Address
ul. Wielicka 265 30-663
Kraków, PL
Kraków, PL
CEO
Jaroslaw Furdal
Website
voxel.pl
IPO
2011-10-11
ISIN PLVOXEL00014
Description
Voxel S.A. manages an extensive chain of facilities dedicated to diagnostic medical imaging. The company's offerings encompass a broad range of advanced imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and single photon emission computed tomography (SPECT). Furthermore, Voxel S.A. provides teleradiology and outsourcing solutions within the diagnostic imaging sector, alongside developing information systems specifically designed for hospitals and diagnostic centers. The firm also undertakes ventures focused on equipping and implementing new diagnostic laboratories. Established in 2005 and headquartered in Kraków, Poland, Voxel S.A. maintains its operational presence through 33 specialized laboratories situated in 21 Polish cities.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
PLN110.80
-0.20 (-0.18%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
13.7K
Beta
0.56
Float Shares
5.94M
Free Float %
56.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +16.14% | +18.95% | +13.11% | -17.03% | -19.40% | -7.07% | -26.81% | +139.92% | +158.58% | +531.64% | +679.31% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
110.80
DCF (Unlevered)
222.56
+100.9%
DCF (Levered)
185.36
+67.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.59
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Medical - Diagnostics & Research: +7.9%+15.0% ★ Q1'26: -0.4% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+2.4% Q1'26: +31.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+10.4% Q1'26: +19.2% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+23.0% ★ Q1'26: +27.0% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+18.4% ★ Q1'26: +21.8% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.0% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.98× Q1'26: 0.88× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
132.05M
est: 126.46M (+4.4%)
|
120.66M
est: 125.30M (-3.7%)
|
152.16M
est: 132.60M (+14.8%)
|
170.41M
est: 179.20M (-4.9%)
|
211.66M
est: 227.10M (-6.8%)
|
327.64M
est: 245.40M (+33.5%)
|
442.66M
est: 260.90M (+69.7%)
|
414.80M
est: 393.83M (+5.3%)
|
424.18M
est: 476.19M (-10.9%)
|
507.77M
est: 507.07M (+0.1%)
|
583.79M
est: 587.96M (-0.7%)
|
547.00M
532.15M – 561.85M
-7.0% YoY
|
565.00M
535.39M – 594.61M
+3.3% YoY
|
624.00M
607.06M – 640.94M
+10.4% YoY
|
762.40M
741.70M – 783.10M
+22.2% YoY
|
| EBITDA |
34.14M
est: 39.07M (-12.6%)
|
29.90M
est: 38.72M (-22.8%)
|
39.20M
est: 40.97M (-4.3%)
|
45.88M
est: 55.37M (-17.1%)
|
56.22M
est: 70.17M (-19.9%)
|
84.24M
est: 75.83M (+11.1%)
|
131.28M
est: 80.62M (+62.8%)
|
118.93M
est: 121.69M (-2.3%)
|
151.49M
est: 153.51M (-1.3%)
|
176.42M
est: 163.46M (+7.9%)
|
189.14M
est: 189.54M (-0.2%)
|
176.34M
171.55M – 181.12M
-7.0% YoY
|
182.14M
172.59M – 191.69M
+3.3% YoY
|
201.16M
195.70M – 206.62M
+10.4% YoY
|
245.78M
239.10M – 252.45M
+22.2% YoY
|
| EBIT |
20.97M
est: 27.38M (-23.4%)
|
17.36M
est: 27.13M (-36.0%)
|
25.92M
est: 28.71M (-9.7%)
|
32.12M
est: 38.80M (-17.2%)
|
33.31M
est: 49.17M (-32.2%)
|
50.19M
est: 53.13M (-5.5%)
|
95.22M
est: 56.49M (+68.6%)
|
79.62M
est: 85.27M (-6.6%)
|
112.78M
est: 110.38M (+2.2%)
|
128.74M
est: 117.53M (+9.5%)
|
133.99M
est: 136.28M (-1.7%)
|
126.79M
123.35M – 130.23M
-7.0% YoY
|
130.96M
124.10M – 137.82M
+3.3% YoY
|
144.64M
140.71M – 148.56M
+10.4% YoY
|
176.72M
171.92M – 181.51M
+22.2% YoY
|
| Net Income |
14.34M
est: 12.20M (+17.5%)
|
11.00M
est: 9.88M (+11.3%)
|
19.80M
est: 14.93M (+32.6%)
|
23.37M
est: 16.05M (+45.7%)
|
22.97M
est: 17.67M (+30.0%)
|
33.96M
|
70.55M
|
44.43M
est: 45.90M (-3.2%)
|
74.20M
est: 89.41M (-17.0%)
|
96.45M
est: 94.35M (+2.2%)
|
98.53M
est: 98.53M (+0.0%)
|
84.02M
81.06M – 86.99M
-14.7% YoY
|
99.77M
96.25M – 103.30M
+18.8% YoY
|
112.38M
108.41M – 116.34M
+12.6% YoY
|
152.29M
146.91M – 157.66M
+35.5% YoY
|
| SGA |
18.47M
est: 7.86M (+134.9%)
|
19.85M
est: 7.79M (+154.9%)
|
19.17M
est: 8.24M (+132.5%)
|
19.46M
est: 11.14M (+74.7%)
|
22.40M
est: 14.12M (+58.6%)
|
27.21M
est: 15.26M (+78.3%)
|
24.73M
est: 16.22M (+52.4%)
|
24.63M
est: 24.49M (+0.6%)
|
24.51M
est: 27.64M (-11.3%)
|
27.82M
est: 29.44M (-5.5%)
|
36.46M
est: 34.13M (+6.8%)
|
31.76M
30.89M – 32.62M
-7.0% YoY
|
32.80M
31.08M – 34.52M
+3.3% YoY
|
36.23M
35.24M – 37.21M
+10.4% YoY
|
44.26M
43.06M – 45.46M
+22.2% YoY
|
| EPS |
1.36
est: 1.16 (+17.1%)
|
1.05
est: 0.94 (+11.6%)
|
1.89
est: 1.42 (+32.9%)
|
2.23
est: 1.53 (+46.0%)
|
2.19
est: 1.68 (+30.2%)
|
3.23
|
6.72
|
4.23
est: 4.37 (-3.2%)
|
7.70
est: 8.51 (-9.6%)
|
9.18
est: 8.98 (+2.2%)
|
9.40
est: 9.44 (-0.4%)
|
8.00
7.72 – 8.28
-15.3% YoY
|
9.50
9.16 – 9.84
+18.8% YoY
|
10.70
10.32 – 11.08
+12.6% YoY
|
14.50
13.99 – 15.01
+35.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
98.14M
OE per share TTM
9.35
Owner's Yield
8.27%
Maintenance CapEx ratio
8.01%
Maint CapEx / Avg PPE
63.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 6 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 109.4K | 0.65% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 20.1K | 0.44% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 7.4K | 0.56% |
| 4 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 4.8K | 0.07% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 53.8K | 0.39% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 42.9K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
414.8K
Shares Outstanding
10.50M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jaroslaw Furdal | Chairman of the Management Board | 660.0K | male |
| Grzegorz Rutkowski | Vice Chairman of the Management Board | 648.0K | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VOX.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
